A New Medical Record Proposal to the Prognostic Risk Assessment for MRONJ in Oncologic Patients: “Sapienza Head and Neck Unit” Proposal

Medication-related osteonecrosis of the jaw (MRONJ) is an adverse event associated with antiresorptive and antiangiogenic drugs. The use of these drugs in the treatment of cancer patients with bone metastasis is necessary and standardized in the literature. A multidisciplinary approach for the patient’s management is strongly recommended. Therefore, it should be necessary to integrate the path of these subjects with a dedicated dental screening in order to first assess the individual risk of developing a MRONJ, and then to plan dental treatments and oral hygiene sessions, and finally to schedule a follow-up to intercept and treat early osteonecrosis. The aim of this manuscript is to propose a new simple medical report to evaluate patients affected by metastatic bone cancer in order to reduce the risk of developing MRONJ.

[1]  P. Vescovi,et al.  Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020 , 2020, International journal of environmental research and public health.

[2]  Stefano Di Carlo,et al.  Head and Neck Osteosarcoma—The Ongoing Challenge about Reconstruction and Dental Rehabilitation , 2020, Cancers.

[3]  P. Marchetti,et al.  Tobacco, Alcohol and Family History of Cancer as Risk Factors of Oral Squamous Cell Carcinoma: Case-Control Retrospective Study , 2020, Applied Sciences.

[4]  A. Polimeni,et al.  Does Medication-Related Osteonecrosis of the Jaw Influence the Quality of Life of Cancer Patients? , 2020, Biomedicines.

[5]  A. Ciolfi,et al.  Timing for implant placement in patients treated with radiotherapy of head and neck. , 2019, La Clinica terapeutica.

[6]  N. Yarom,et al.  Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Kuroshima,et al.  Medication-related osteonecrosis of the jaw: A literature review. , 2019, Journal of oral biosciences.

[8]  V. Tombolini,et al.  Crestal bone loss around dental implants placed in head and neck cancer patients treated with different radiotherapy techniques: a prospective cohort study. , 2019, International journal of oral and maxillofacial surgery.

[9]  V. Tombolini,et al.  Management of salivary gland malignant tumor: the Policlinico Umberto I, "Sapienza" University of Rome Head and Neck Unit clinical recommendations. , 2017, Critical reviews in oncology/hematology.

[10]  S. Di Carlo,et al.  Prosthetic rehabilitation involving the use of implants following a fibula free flap reconstruction in the treatment of Osteosarcoma of the maxilla: a case report. , 2017, La Clinica terapeutica.

[11]  A. Mannocci,et al.  Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: a pilot study. , 2017, La Clinica terapeutica.

[12]  V. Tombolini,et al.  Follow-up program in head and neck cancer. , 2017, Critical reviews in oncology/hematology.

[13]  S. Di Carlo,et al.  Maxillofacial Prosthesis in Dentofacial Traumas: A Retrospective Clinical Study and Introduction of New Classification Method , 2017, BioMed research international.

[14]  A. Ciolfi,et al.  Pleomorphic adenoma rehabilitative treatment in growing up patient: a 20-years follow-up. , 2016, European review for medical and pharmacological sciences.

[15]  A. Polimeni,et al.  Adalimumab: Another Medication Related to Osteonecrosis of the Jaws? , 2016, Case reports in dentistry.

[16]  J. Compston,et al.  Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015 , 2016, Osteoporosis International.

[17]  G. Pompa,et al.  Retrospective review of 78 rehabilitated head and neck postoncological patients: a new classification method. , 2016, Minerva stomatologica.

[18]  Y. Kitamura,et al.  Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study. , 2015, Biological & pharmaceutical bulletin.

[19]  Y. Fujiwara,et al.  Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer , 2015, Supportive Care in Cancer.

[20]  G. di Carlo,et al.  Survival of dental implants in patients with oral cancer treated by surgery and radiotherapy: a retrospective study , 2015, BMC oral health.

[21]  T. Dodson,et al.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[22]  S. Annibali,et al.  The “CROMa” Project: A Care Pathway for Clinical Management of Patients with Bisphosphonate Exposure , 2014, International journal of dentistry.

[23]  G. Bedogni,et al.  Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. , 2014, The British journal of oral & maxillofacial surgery.

[24]  M. Pagnoni,et al.  Keratocystic Odontogenic Tumor Surgical Management: Retrospective Analysis on 77 Patients , 2014 .

[25]  P. Anders,et al.  Osteonecrosis of the jaw - prevention and treatment strategies for oral health professionals. , 2013, Oral oncology.

[26]  M. Pagnoni,et al.  Osteoradionecrosis of a Mandible: A Case Report of Implant-Supported Rehabilitation , 2013 .

[27]  Katsu Takahashi,et al.  Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. , 2012, International journal of oral and maxillofacial surgery.

[28]  F. Saad,et al.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  G. Campisi,et al.  Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ) , 2012, Oral diseases.

[30]  S. Bosco,et al.  Giant Cell Lesion or Langerhans' Cell Histiocytosis of the Mandible? A Case Report , 2012 .

[31]  P. Vescovi,et al.  Observation of pain control in patients with bisphosphonate-induced osteonecrosis using low level laser therapy: preliminary results. , 2011, Photomedicine and laser surgery.

[32]  R. Baron,et al.  Denosumab and bisphosphonates: different mechanisms of action and effects. , 2011, Bone.

[33]  G. Scagliotti,et al.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Falagas,et al.  Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently than Bisphosphonates Alone , 2009, Oncology.

[35]  B. Clarke,et al.  Bisphosphonates: mechanism of action and role in clinical practice. , 2008, Mayo Clinic proceedings.

[36]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[37]  R. Coleman.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[38]  S. DiCarlo.  Quality of Life in Patients Rehabilitated with Palatal Obturator without Reconstruction Versus Fixed Implant-Prosthesis after Reconstruction of Maxillectomy Defects , 2017 .

[39]  G. Bedogni,et al.  Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. , 2015, The British journal of oral & maxillofacial surgery.

[40]  J. Thigpen.  Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma , 2011 .